Looking for an I/O edge, Bristol-Myers fronts $105M to partner with Halozyme as Roche expands pact
After racking up H1 sales of $2.3 billion for its PD-1 star Opdivo, Bristol-Myers Squibb is now fronting $105 million — with a trove of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
